Skip to main content

Table 1 Subject characteristics

From: Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

  a. All (n = 2462) b. SCD (n = 448) c. MCI (n = 490) d. AD-type dementia (n = 1031) e. Non-AD-type dementia (n = 493)
Age, years 66.8 (7.0) 64.4 (6.2)b,c,d 68.2 (6.9)a,c,d 67.3 (7.2)a,b 66.9 (6.8)a,b
Female sex, n (%) 1049 (43) 170 (38)c 181 (37)c 528 (51)a,b,d 170 (34)c
Years of education 11.1 (3.0) 11.9 (3.1)b,c,d 11.4 (3.2)a,c,d 10.8 (2.8)a,b 10.5 (2.9)a,b
MMSE score 23.6 (5.2) 28.3 (1.7)b,c,d 26.5 (2.5)a,c,d 20.4 (5.0)a,b,d 23.0 (5.2)a,b,c,
APOE ε4 allele carriers, n (%) 1186 (54) 158 (35)b,c 242 (49)a,c,d 615 (60)a,b,d 171 (35)b,c
CSF Aβ1–42, pg/ml 667 (289) 906 (277)b,c,d 676 (295)a,c,d 504 (174)a,b,d 781 (278)a,b,c
CSF tau, pg/ml 527 (401) 317 (205)b,c,d 486 (313)a,c,d 705 (406)a,b,d 394 (443)a,b,c
CSF p-tau, pg/ml 70 (37) 52 (25)b,c 70 (35)a,c,d 88 (39)a,b,d 50 (25)b,c
Outcome at follow-up AD-type/no AD-type dementia (% AD-type dementia) 13/235 (5) 146/224 (61)
Average follow-up duration, years 2.93 (1.99) 2.41 (1.46)
  1. Data are mean (SD), unless otherwise specified. Superscript letters indicate that this group shows a statistically significant difference (p < .05) with other groups as labelled with a,b,c,d or e in the column headers
  2. Abbreviations: SCD Subjective cognitive decline, MCI Mild cognitive impairment, AD Alzheimer’s Disease, APOE Apolipoprotein E, CSF Cerebrospinal fluid, 1–42 β-Amyloid 1–42, - Not applicable